Multiple myeloma in a patient with chronic myeloid leukemia: A case report

Chronic myeloid leukemia (CML), a clonal myelo-proliferative disorder of pluripotent hematopoietic stem cells, results from the Philadelphia chromosome (Ph) chromosome. The Ph is from a translocation, t(9;22)(q34q11), that creates a BCR-ABL fusion gene, which is transcribed into proteins with abnorm...

Full description

Saved in:
Bibliographic Details
Published in:Oncology letters 2023-06, Vol.25 (6), p.1, Article 244
Main Authors: Li, Xiao-Lan, Li, Min, Wang, Ling-Zhi, Liang, Min, Tian, Juan, Shi, Zi-Wei, Song, Kui
Format: Article
Language:English
Subjects:
B cells
Bone marrow
Cancer
Case Report
Case reports
Cell cycle
Chemotherapy
Chronic myeloid leukemia
Fever
Flow cytometry
Granulocytes
Hematology
Hematopoietic stem cells
Hypotheses
Immunoglobulin G
Kinases
Leukemia
Medical research
Medicine, Experimental
Multiple myeloma
Oncology
Oncology, Experimental
Patients
Plasma
Radiation
Stem cells
Tumors
Tyrosine
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Chronic myeloid leukemia (CML), a clonal myelo-proliferative disorder of pluripotent hematopoietic stem cells, results from the Philadelphia chromosome (Ph) chromosome. The Ph is from a translocation, t(9;22)(q34q11), that creates a BCR-ABL fusion gene, which is transcribed into proteins with abnormal tyrosine kinase activity, driving the abnormal proliferation of white blood cells. Multiple myeloma (MM) is a proliferation disorder of plasma cells derived from a single clone, which may lead to uncontrolled growth, kidney injury, destructive bone lesions, hypercalcemia and anemia. It is extremely rare that MM and CML should occur in the same patient either synchronously or metachronously. To date, MM accompanied with CML has only been reported in limited studies, and the the cause behind the occurrence of both malignancies together is not understood. With the advent of novel therapies, the survival time in patients with CML and MM has improved. Therefore, the further investigation of the pathophysiology and clinical characteristics of these cases is valuable. The present study reports the case of a 79-year-old male who had been diagnosed with CML and treated with tyrosine kinase inhibitor, and then developed immunoglobulin G-[kappa] MM after 6 years. This report should provide valid raw data for clinical research.
ISSN:1792-1074
1792-1082
DOI:10.3892/ol.2023.13830